Phase 1 Trial of TAK-755, Potential VOC-easing Therapy, Enrolling in US

Phase 1 Trial of TAK-755, Potential VOC-easing Therapy, Enrolling in US

314190

Phase 1 Trial of TAK-755, Potential VOC-easing Therapy, Enrolling in US

A Phase 1 trial evaluating the safety and pharmacological properties of TAK-755 — Takeda’s experimental therapy for painful vaso-occlusive crises (VOCs) — in adults with sickle cell disease (SCD) is actively recruiting patients for its intermediate dose group. SCD patients, ages 18–65 years, who had no VOCs in the previous 21 days and did not receive a blood transfusion either within the past month or two transfusions in the past three months, are being enrolled at…

You must be logged in to read/download the full post.